Friday, 16 October 2026European Markets

COFINA,SGPS Stock Impressive Rise On Monday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with COFINA,SGPS (CFN.LS) rising 14.41% to €1.35 on Monday, after two successive sessions in a row of gains. PSI dropped 0.34% to €6,655.83, following the last session's downward trend on what was a somewhat negative trend exchanging session today.

COFINA,SGPS's last close was €1.18, 136% higher than its 52-week high of €0.50.

About COFINA,SGPS

Cofina, SGPS, S.A., through its subsidiaries, engages in the publication of newspapers and magazines in Portugal. The company offers newspapers, including Correio da Manha, a daily newspaper; Record, a daily sport newspaper; Negocios, an economic newspaper; and Destak, a free newspaper. It also provides Sábado, an entertainment weekly magazine; TV Guia, weekly television magazine; Máxima, an online publication that develops topics related to culture, fashion, beauty, health and well-being, and travel and lifestyle; Flash, an online publication which addresses the social current affairs of national and international public figures; and Correio da Manhã TV (cmTV), a cable platform. In addition, the company engages in the investment management activities. The company was incorporated in 1990 and is headquartered in Porto, Portugal.

Earnings Per Share

As for profitability, COFINA,SGPS has a trailing twelve months EPS of €-1.4.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -24.26%.

More news about COFINA,SGPS (CFN.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com